{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:56:50Z","timestamp":1768881410599,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014812","name":"Nordic Pharma Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00806-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:10:28Z","timestamp":1764767428000},"page":"157-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05082805","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-6496","authenticated-orcid":false,"given":"C\u00e9cile","family":"Gaujoux-Viala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6113-166X","authenticated-orcid":false,"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6290-6110","authenticated-orcid":false,"given":"Eric","family":"Senbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3780-9418","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Herman-Demars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8554-4281","authenticated-orcid":false,"given":"Jennifer","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-8070","authenticated-orcid":false,"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"5","key":"806_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"KB Almutairi","year":"2021","unstructured":"Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669\u201376.","journal-title":"J Rheumatol"},{"key":"806_CR2","unstructured":"Personnes prises en charge pour polyarthrite rhumato\u00efde et maladies apparent\u00e9es en 2022. Caisse Nationale de l'Assurance Maladie\u2014CNAM [updated 2024 Dec 06]. https:\/\/www.assurance-maladie.ameli.fr\/sites\/default\/files\/2022_fiche_polyarthrite-rhumatoide-et-maladies-apparentees.pdf."},{"issue":"10","key":"806_CR3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/ard.2004.029199","volume":"64","author":"F Guillemin","year":"2005","unstructured":"Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005;64(10):1427\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"806_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","volume":"86","author":"C Daien","year":"2019","unstructured":"Daien C, Hua C, Gaujoux-Viala C, et al. Update of French Society for Rheumatology recommendations for managing rheumatoid arthritis. Jt Bone Spine. 2019;86(2):135\u201350.","journal-title":"Jt Bone Spine"},{"issue":"1","key":"806_CR5","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","volume":"16","author":"H Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56.","journal-title":"Arthritis Res Ther"},{"key":"806_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152031","volume":"55","author":"J Xu","year":"2022","unstructured":"Xu J, Xiao L, Zhu J, Qin Q, Fang Y, Zhang JA. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022;55:152031.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"806_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","volume":"81","author":"C Gaujoux-Viala","year":"2014","unstructured":"Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Jt Bone Spine. 2014;81(4):287\u201397.","journal-title":"Jt Bone Spine"},{"issue":"1","key":"806_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/rheumatology\/kep340","volume":"49","author":"B Fautrel","year":"2010","unstructured":"Fautrel B, Benhamou M, Foltz V, et al. Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. Rheumatology (Oxford). 2010;49(1):147\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"806_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3899\/jrheum.080762","volume":"36","author":"M Benhamou","year":"2009","unstructured":"Benhamou M, Rincheval N, Roy C, et al. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol. 2009;36(5):934\u201342.","journal-title":"J Rheumatol"},{"issue":"1","key":"806_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"806_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105790","volume":"91","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Kedra J, Juge P-A, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Jt Bone Spine. 2024;91(6):105790.","journal-title":"Jt Bone Spine"},{"issue":"5","key":"806_CR12","first-page":"689","volume":"56","author":"E Choy","year":"2017","unstructured":"Choy E, Aletaha D, Behrens F, et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(5):689\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"806_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003075","author":"C Gaujoux-Viala","year":"2023","unstructured":"Gaujoux-Viala C, Bergmann JF, Goguillot M, et al. Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003075.","journal-title":"RMD Open"},{"issue":"7","key":"806_CR14","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/acr.23914","volume":"72","author":"M Inoue","year":"2020","unstructured":"Inoue M, Kanda H, Tateishi S, Fujio K. Evaluation of response criteria in rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2020;72(7):942\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"806_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3899\/jrheum.090375","volume":"37","author":"S Sekhon","year":"2010","unstructured":"Sekhon S, Pope J, Canadian Scleroderma Research Group, Baron M. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. J Rheumatol. 2010;37(3):591\u20138.","journal-title":"J Rheumatol"},{"issue":"12","key":"806_CR16","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/annrheumdis-2017-211268","volume":"76","author":"C Gaujoux-Viala","year":"2017","unstructured":"Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Ann Rheum Dis. 2017;76(12):2054\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"806_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","volume":"25","author":"JY Jung","year":"2023","unstructured":"Jung JY, Lee E, Kim JW, et al. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry. Arthritis Res Ther. 2023;25(1):174.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"806_CR18","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"806_CR19","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1007\/s12325-023-02607-w","volume":"40","author":"V Rosenberg","year":"2023","unstructured":"Rosenberg V, Chodick G, Xue Z, Faccin F, Amital H. Real-world data of adherence and drug survival of biologics in treatment-naive and treatment-experienced adult patients with rheumatoid arthritis. Adv Ther. 2023;40(10):4504\u201322.","journal-title":"Adv Ther"},{"issue":"9","key":"806_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","volume":"79","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel AE, Hazes JM, van der Helm-van MA, de Jong PHP. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79(9):1174\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"806_CR21","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2020-217528","volume":"79","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel AE, Kuijper TM, et al. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. Ann Rheum Dis. 2020;79(12):1550\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"806_CR22","first-page":"343","volume":"84","author":"C Gaujoux-Viala","year":"2017","unstructured":"Gaujoux-Viala C. \u00c9valuation de l\u2019activit\u00e9 de la polyarthrite rhumato\u00efde. Rev Rhum Monogr. 2017;84(4):343\u20136.","journal-title":"Rev Rhum Monogr"},{"issue":"6","key":"806_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","volume":"78","author":"E van Mulligen","year":"2019","unstructured":"van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019;78(6):746\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"806_CR24","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1093\/rheumatology\/keac154","volume":"61","author":"AEM Looijen","year":"2022","unstructured":"Looijen AEM, van Mulligen E, van der Helm-van Mil AHM, de Jong PHP. Tapering subcutaneous methotrexate causes more disease flares compared with tapering oral administration in established rheumatoid arthritis patients. Rheumatology (Oxford). 2022;61(8):e216\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"806_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"806_CR26","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","volume":"60","author":"AA Sherbini","year":"2021","unstructured":"Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2021;60(9):4001\u201317.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"806_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/ard-2023-224032","volume":"82","author":"LF Perez-Garcia","year":"2023","unstructured":"Perez-Garcia LF, Roder E, Krijthe BP, et al. Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX). Ann Rheum Dis. 2023;82(8):1068\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"806_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"key":"806_CR29","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors. 2021."},{"issue":"5","key":"806_CR30","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40744-024-00696-9","volume":"11","author":"L Bessette","year":"2024","unstructured":"Bessette L, Florica B, Naik L, et al. A Canadian retrospective chart review evaluating concomitant methotrexate de-escalation patterns in patients with rheumatoid arthritis treated with biologic or targeted synthetic DMARDs. Rheumatol Ther. 2024;11(5):1165\u201380.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"806_CR31","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1136\/annrheumdis-2013-203684","volume":"73","author":"JE Pope","year":"2014","unstructured":"Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6\u00a0months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2014;73(12):2144\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"806_CR32","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2665-9913(19)30005-0","volume":"1","author":"SB Cohen","year":"2019","unstructured":"Cohen SB, Pope J, Haraoui B, et al. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11\u00a0mg once daily plus methotrexate (ORAL shift): a randomised, phase\u00a03b\/4, non-inferiority trial. Lancet Rheumatol. 2019;1(1):e23\u201334.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"806_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clinthera.2018.01.002","volume":"40","author":"SL Goss","year":"2018","unstructured":"Goss SL, Klein CE, Jin Z, et al. Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO trial. Clin Ther. 2018;40(2):309\u201319.","journal-title":"Clin Ther"},{"issue":"9","key":"806_CR34","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","volume":"59","author":"K Bechman","year":"2020","unstructured":"Bechman K, Oke A, Yates M, et al. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2020;59(9):2563\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"806_CR35","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1093\/rheumatology\/keaa850","volume":"60","author":"C Roubille","year":"2021","unstructured":"Roubille C, Coffy A, Rincheval N, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021;60(8):3738\u201346.","journal-title":"Rheumatology (Oxford)"},{"key":"806_CR36","doi-asserted-by":"crossref","unstructured":"Bijlsma JWJ. Annals of the Rheumatic Diseases collection on glucocorticoids (2020\u20132023): novel insights and advances in therapy. Ann Rheum Dis. 2024;83(1):4\u20138.","DOI":"10.1136\/ard-2023-224847"},{"issue":"1","key":"806_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13075-022-02824-8","volume":"24","author":"G Sakellariou","year":"2022","unstructured":"Sakellariou G, Scire CA, Rumi F, et al. Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases. Arthritis Res Ther. 2022;24(1):144.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"806_CR38","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard-2023-223977","volume":"82","author":"AAH Almayali","year":"2023","unstructured":"Almayali AAH, Boers M, Hartman L, et al. Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023;82(10):1307\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"806_CR39","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","volume":"46","author":"M Mierau","year":"2007","unstructured":"Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46(6):975\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 6","key":"806_CR40","doi-asserted-by":"publisher","first-page":"vi16","DOI":"10.1093\/rheumatology\/kes281","volume":"51","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Massarotti EM. The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16-20.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"806_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105253","volume":"89","author":"P Richette","year":"2022","unstructured":"Richette P, Allez M, Descamps V, et al. Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases. Jt Bone Spine. 2022;89(1):105253.","journal-title":"Jt Bone Spine"},{"issue":"3","key":"806_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jbspin.2020.03.013","volume":"87","author":"M Benucci","year":"2020","unstructured":"Benucci M, Damiani A, Infantino M, Manfredi M, Quartuccio L. Old and new antirheumatic drugs for the treatment of COVID-19. Joint Bone Spine. 2020;87(3):195\u20137.","journal-title":"Joint Bone Spine"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00806-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00806-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00806-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:27Z","timestamp":1768834347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00806-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00806-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C\u00e9cile Gaujoux-Viala: AbbVie; Alfasigma; Amgen; Biocon; Biogen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Celltrion; Eli Lilly; Galapagos; Gilead Sciences; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB Pharma and Viatrix. Emmanuelle Dernis: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Roche-Chuga\u00ef, Sandoz, Sanofi and UCB Pharma. Eric Senbel: Abbvie, Celltrion, Fresenius Kabi, Lilly, Medac, Nordic Pharma, Novartis, Pfizer, Sandoz and UCB. H\u00e9l\u00e8ne Herman-Demars and Jennifer Becker: employees Nordic Pharma France. Ren\u00e9-Marc Flipo: Abbvie, Bristol-Myers Squibb, Eli-Lilly, Janssen, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chuga\u00ef, Sandoz and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved on 12 November 2018, by an independent ethics committee (Comit\u00e9 de Protection des Personnes Sud M\u00e9diterran\u00e9e V; Reference 18.068). All participating study sites accepted the single ethics committee approval. The ethics committee expressly authorized the use of oral non-opposition, as permitted for non-interventional research conducted in France and involving no risk or constraint beyond routine clinical practice. Participants received comprehensive written information about the study objectives, procedures, and their rights, in compliance with Articles L.1121-1 and L.1122-1-1 of the French Public Health Code. Oral non-opposition to the collection of their personal data was obtained prior to participant inclusion and documented in the study records, as required by local regulations governing non-interventional studies in France. All data were processed in compliance with the reference methodology MR-003 from the French Data Protection Authority (CNIL), ensuring the protection of participant privacy and data integrity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}